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ES-62 is a phosphorylcholine (PC)-containing glycoprotein secreted by the filarial nematode 
Acanthocheilonemaviteae that acts to modulate the host immune response to promote the establishment of chronic 
helminth infection. Reflecting its anti-inflammatory actions, we have previously reported that ES-62 protects mice 
from developing Collagen-Induced Arthritis (CIA): thus, as this helminth-derived product may exhibit therapeutic 
potential in Rheumatoid Arthritis (RA), it is important to understand the protective immunoregulatory mechanisms 
triggered by ES-62 in this model in vivo. We have established to date that ES-62 acts by downregulating pathogenic 
Th17/IL-17-mediated responses and up regulating the regulatory cytokine IL-10. In addition, our studies have 
identified thatIL-22, another member of the IL-10 family of cytokines, exerts dual pathogenic and protective roles in 
this model of RA with ES-62 harnessing the cytokine’s inflammation-resolving and tissue repair properties in the joint 
during the established phase of disease. Here, we discuss the counter-regulatory roles of IL-22 in the murine model of 
CIA and present additional novel data showing thatES-62 selectively induces γδ T cells with the capacity to induce 
IL-22 production and that T cells with the capacity to produce IL-22, but not IL-17, induced during CIA can be 
identified by their expression of TLR4. Moreover, we also show that treatment of mice undergoing CIA with the active 
PC moiety of ES-62, in the form of PC conjugated to BSA, is not only sufficient to mimic the ES-62-dependent 
suppression of pathogenic IL-17 responses shown previously but also that of the IL-22 and IL-10 up-regulation 
observed with the parasitic worm product during CIA. These findings not only reinforce the potential of IL-22, firstly 
described as a Th17-related pro-inflammatory cytokine, as a protective factor in arthritis but also suggest that drugs 
based on the PC moiety found in ES-62 may be able to harness the joint-protecting activities ofIL-22 therapeutically.  
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Introduction 
ES-62 is a phosphorylcholine (PC)-containing 
glycoprotein secreted by the rodent filarial nematode 
Acanthocheilonemaviteae and a homologue of 
excretory-secretory products that can be detected in the 
bloodstream of humans infected with Brugiamalayi and 
Onchocerca volvulus 
[1]
. Our early in vitro studies 
revealed that this parasite-derived molecule exhibits a 
broad range of immunomodulatory effects, for example 
the dampening of the pro-inflammatory responses of 
macrophages and dendritic cells
[2, 3]
, that likely promote 
persistence of the parasite in the host without severely 
immunocompromising it. Although its mechanism of 
action is not yet fully understood, TLR4 is a major target 
of ES-62 
[4]
 and most of its anti-inflammatory properties 
depend on its unusual post-translational addition of PC: 
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thus, when PC is chemically linked to an irrelevant 
protein such as BSA or ovalbumin, as with ES-62, it 
inhibits full activation of macrophages and DCs 
following TLR stimulation in a TLR4-dependent 
manner
[5]
.  
In accordance with the Hygiene Hypothesis 
[6]
 that has 
led to the proposal that the recent dramatic increase in 
allergy and autoimmune diseases in industrialized 
countries is related to the eradication of parasitic 
infections, a wide range of studies have shown infection 
with helminths to be protective against such disorders in 
experimental models, suggesting that such parasites or 
their immunomodulatory products could be exploited 
therapeutically. Reflecting this, we have shown that 
treatment with ES-62, either prophylactically or 
therapeutically, reduces disease severity and incidence of 
Collagen-Induced Arthritis (CIA), a murine model of 
human Rheumatoid Arthritis (RA)
[7]
 andPC-BSA is able 
to protect mice in a similar fashion to that of ES-62 
[8, 9]
. 
An increasing number of studies have shown that 
helminths and their secreted products exert their 
anti-inflammatory effects by actively modulating host 
immune effect or mechanisms, for example, by reducing 
aberrant Th1or Th2 responses and 
up-regulatingIL-10-dependent regulatory pathways 
[10-12]
. 
Indeed, some of these actions have been associated with 
the mechanism of action underlying ES-62-mediated 
protection in CIA. Thus, protection was first associated 
with suppressed Th1 responses, reduced levels of 
collagen-specific IgG2a antibodies and increased IL-10 
production 
[7, 13]
. However, ES-62 failed to protect against 
other Th1-driven models of disease 
[14, 15]
, suggesting that 
alternative pathways might be targeted in CIA. Indeed, 
ES-62-mediated protection was subsequently shown to be 
associated with down regulation of IL-17 production, a 
finding consistent with increasing evidence that this 
cytokine is a major pathogenic driver in 
RAasIL-17induceshyperplasia and proliferation of 
synoviocytes, production of pro-inflammatory mediators 
and promotion of TLR-dependent responses and 
recruitment of immune system cells including T cells, B 
cells and neutrophils 
[16-18]
. Interestingly, ES-62 
down-regulates IL-17 production by a multi-pronged 
mechanism, inhibiting Th17 polarization both directly 
and indirectly, the latter via the suppression of IL-6 and 
IL-23release by DCs, key cytokines in DC-priming of 
Th17 differentiation. ES-62 also targets DCs to modulate 
the cross-talk between γδ T cells and DCs, resulting in 
reduced levels of IL-17 production by the innate 
lymphocytes. Collectively, these actions result in 
downregulated expression of IL-17 in the joints of mice 
with CIA and reduced synovial inflammation
[19]
. 
Importantly, as biologics targeting IL-17 have resulted in 
some opportunistic fungal infections under clinical trial, 
IL-17-producing NK cells which have been shown to be 
protective in such infections remain unaffected in 
ES-62-treated mice undergoing CIA
[20]
. Thus ES-62 
attenuates IL-17-mediated responses without fully 
inhibiting them, as a result suppressing pathogenic, but 
not infection-combating sources of IL-17 and these 
findings may go some way to explaining why helminth 
infections or ES-62-based treatments do not substantially 
immunocompromise the host.  
More recently, we have investigated the effect of 
ES-62 on another component of the IL-23/IL-17 
inflammatory axis in autoimmune arthritis, namely IL-22 
which had also been reported to be a pro-inflammatory 
cytokine in RA 
[21, 22]
. Consistent with this, we showed 
that neutralisation of IL-22 prior to onset of disease 
blocks joint pathology. However, we have also shown 
that IL-22 is required for ES-62’s anti-arthritic effects, 
via a mechanism in which IL-22-signalling desensitizes 
synovial fibroblast (SF) responses to pro-inflammatory 
factors such as IL-17 in the joint 
[23]
. As a result, SFs 
produce less IL-6 and the number of neutrophils 
infiltrating the joints is significantly reduced. These 
findings are consistent with increasing evidence 
suggesting that IL-22 can play dual pathogenic and, 
reflecting its wound healing properties 
[24]
, protective 
roles in RA. It is therefore essential to fully understand 
the role(s) of IL-22 in the pathogenesis of arthritis and 
the resolution of inflammation and protection against 
joint damage induced by the helminth product in order to 
translate these potentially therapeutic actions to the clinic. 
The aim of this report is therefore to provide further 
insight into the sources of IL-22 modulated by ES-62 in 
mice with CIA and in particular we show that a subset of 
γδ T cells that express TLR4 in vivo is a major potential 
producer of such protective IL-22. In addition, we also 
report that PC-BSA mimics the ability of ES-62 to 
up-regulate IL-22 production during protection from 
CIA: thus as we have recently provided proof of principle 
that small drug-like PC-based compounds can be 
protective in mouse models of arthritis and asthma
[9, 25]
, 
this latter finding highlights the novel potential of 
parasite-derived products to harness the therapeutic 
properties of IL-22 in RA.  
Material and Methods 
CIA. Animals were maintained in the Biological 
Services Units in accordance with the Home Office UK 
LicencesPPL60/3580, PPL60/3119 andPIL60/12183 and 
the Ethics Review Boards of the Universities of Glasgow 
and Strathclyde. CIA was induced in male DBA/1 mice 
(8-10 weeks old; Harlan Olac; Bicester, UK) by 
intradermal immunization with bovine type II collagen 
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(CII, MD Biosciences) in complete Freund’s adjuvant 
(FCA) and mice were treated with purified 
endotoxin-free ES-62 from A. viteae or PC-BSA (2 
µg/dose)or PBS subcutaneously on days -2, 0 and 21
[7, 8]
. 
Mice were monitored for clinical symptoms of arthritis: 
severity scores represent 0=normal; 1=erythema; 
2=erythema plus swelling; 3=extension of swelling; 
4=loss of function, and the disease score is the sum for 
the four limbs.  
Ex vivo analysis.DLN cells (10
6
/ml) were stimulated 
in the presence and absence of PMA (50 ng/ml) plus 
ionomycin (500 ng/ml) for 1 h before being incubated 
with 10 μg/ml Brefeldin A (Sigma-Aldrich, UK) for 5 h 
at 37
o
C with 5% CO2. Live cells were discriminated by 
the LIVE/DEAD fixable aqua dye (BioLegend, UK) and 
phenotypic markers labelled using FITC-conjugated 
anti-CD49b (BioLegend, UK), APC-conjugated anti-γδ 
TCR (eBioscience, UK)and biotin-anti TLR4 antibodies 
before the cells were fixed and permeabilized according 
to BioLegend protocols. Pacific Blue-conjugated 
streptavidin was used for detection of biotinylated 
antibodies. Cytokines were stained using 
PerCP-Cy5.5–conjugated anti–IL-17A (BioLegend, UK) 
or PE-conjugated anti–IL-22 antibodies (R&D Systems, 
UK) for 30 minutes prior to analysis by flow cytometry, 
with gating according to appropriate isotype controls
[19, 
Figure 1. Kinetic analysis of IL-22-producing NK and T cells in DLN of mice with CIA. 
ES-62- and PBS-treated mice undergoing CIA were culled every 7 days (n=4 for each 
treatment group at each time-point) and IL-22 expression by DLN cells analysed by 
intracellular flow cytometry. Proportions of spontaneouslyIL-22-producing, CD49b+NK T cells 
(A) and γδ+ TCR+T cells (B)from individual mice were evaluated as described in the Material 
and Methods. The proportions of IL-17-producing NK (C) and T cells (D) were also analysed 
at d28. Red symbols represent CIA mice treated with PBS whilst black symbols represent 
mice treated with ES-62. Values are the mean ± SEM of 4 individual mice at each time. 
*p<0.05, **p<0.01. 
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23]
. 
Cytokine analysis. Serum levels of IL-22 and IL-10 
were determined by ELISA, according to the 
manufacturers' recommendations ((R&D Systems; 
Biolegend). 
Statistical analysis. Data were analyzed by Student’s 
unpaired 1-tailed t-test. Articular scores were analysed by 
the Mann-Whitney test. P values *<0.05 were considered 
significant. 
Results and Discussion 
ES-62 differentially regulates IL-22 production by 
γδ and NK T cells in DLN from mice undergoing CIA. 
Protection by ES-62 in the CIA model has been 
associated with counter-regulation of IL-17 and IL-22 
levels in serum and joints during the established phase of 
pathology, with exposure to the parasite product 
elevating IL-22 but reducing IL-17 levels 
[19, 23]
. 
Similarly, exposure to ES-62reduces IL-17, but not IL-22 
production by DLN and joint cells ex vivo and analysis 
revealed these cytokines to be predominantly produced 
by distinct populations of cells at both sites 
[19, 23]
. 
Moreover, whilst ES-62 inhibited the levels of both 
spontaneous and PMA/ionomycin-stimulated IL-17 
production by CD4
+
 DLN cells, it only reduced the 
proportion of unstimulated CD4
+
DLN cells expressing 
IL-22 
[23]
. However, although we have shown the parasite 
product to additionally suppress the levels of IL-17
+
γδT 
cells whilst leaving the levels ofIL-17-producing NK 
cells unaffected 
[26]
, the effects of ES-62 on IL-22 
production by these subsets of innate lymphocytes was 
not investigated. We therefore decided to evaluate this in 
order to potentially identify a source of protective IL-22 
production in the DLN during CIA progression (Fig.1). 
Consistent with our previous observations that exposure 
to ES-62 appeared to have little effect on the levels of 
IL-22-producing DLN cells 
[23]
, whilst kinetic analysis 
suggested that the proportion of both NK and γδ T cells 
expressing IL-22 was elevated in those DLN from ES-62 
exposed mice undergoing CIA following challenge (day 
21; Fig. 1A&B), this only reached significance for T cells 
(at d28; Fig. 1B). By contrast, the proportion of IL-17
+
 
but not NK IL-17
+
 T cells was reduced at this time point 
(Fig. 1C&D). These data suggest that T cells, which by 
bridging innate and adaptive immunity play important 
immunoregulatory roles in RA 
[27]
, are selectively 
targeted by ES-62 to modulate the IL-17/IL-22 balance in 
the CIA model to mediate its protective effects. 
Interestingly, this kinetic analysis also revealed, 
consistent with IL-22 playing a pathogenic role during 
the initiation phase of disease that the levels of 
IL-22-producing γδ T cells in the DLN peaked within 
about 7 days and then generally declined with disease 
progression in PBS-treated mice undergoing CIA. By 
contrast, and supporting their proposed protective role, 
exposure to ES-62 helps maintain the levels of IL-22
+
 T 
cells at time points where pathology is normally 
established in the joint. Although we do not know 
whether these cells can migrate to the joint and hence are 
representative of the IL-22-expressing lymphocyte-like 
cells previously shown to be elevated in ES-62-treated 
mice at this stage 
[23]
, these results could suggest that the 
observed increase of IL-22 in serum and joints of 
ES-62-treated mice might be a result of γδ T cell 
modulation rather than effects on conventional Th22 cells 
and may correlate with a report that CD4
+
T cells isolated 
from synovial samples from RA patients were not able to 
produce IL-22 
[22]
.  
IL-22-producing γδ T cells, but not 
IL-17-producing γδ T cells, express Toll-like receptor 
4 (TLR4). It is not clear how ES-62 selectively targets 
but not NK T cells, to render them respectively sensitive 
or resistant to modulation of IL-17/IL-22 production as 
both these cell types express pattern recognition receptors 
(PRR) important in CIA pathogenesis 
[28]
, such as TLR2 
[29]
 and ES-62 has been shown to subvert TLR signalling 
by down regulation of MyD88 in a variety of cell types 
[4, 
19, 30-33]
. However, TLR4 is required for ES-62 action and 
although this PRR is not generally considered to be 
expressed by either or NK T cells, TLR4
+
γδ T cells have 
been described following burn injury 
[34]
 and we have 
recently reported that a population of these cells, but not 
NK T cells can be found in the DLN of mice undergoing 
CIA 
[20]
. Thus, as TLR4 signalling has been reported to 
promote IL-17 production in γδT cells isolated from 
lungs and lymphoid organs 
[35]
, we hypothesised that 
differential expression of this PRR may be involved in 
the selective regulation of IL-17/IL-22 production by γδ 
T cells and NK T cells in the CIA model. Although 
analysis of DLN cells from mice with CIA confirmed 
thatTLR4
+
γδ T cells did not express IL-17 
[20, 28]
, perhaps 
surprisingly, but consistent with our previous findings 
that IL-17 and IL-22 were predominantly expressed by 
distinct populations of DLN cells, we observed a positive 
correlation between IL-22 expression and TLR4 on, but 
not NK, T cells (Fig. 2A & B). This is the first 
observation of IL-22
+
TLR4
+
γδ T cells in the CIA model, 
and this subset may be analogous to the population of 
IL-22
+
IL-17
-
γδ T cells that has been shown to be 
protective in models of colon inflammation 
[36]
 and lung 
fibrosis 
[37]
. A similar association between other cell 
surface markers and cytokine profile expression in γδ T 
cells has previously been reported in that IL-17
+
γδ T cells 
and IFNγ
+ 
γδ T cells differentially express the markers 
CD25 and CD122 respectively 
[38, 39]
, suggesting that 
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expression of particular cell sensors can dictate functional 
γδ T cell responses and thus, phenotyping may allow the 
possibility of distinguishing potentially protective 
IL-22
+
γδ T cells from pathogenic IL-17
+
γδ T cells. 
Whether ES-62 can induce "protective" IL-22
+
 T cells via 
TLR4 signalling and/or differentially and temporally 
modulate IL-17 and IL-22 production by distinct subsets 
of T cells is currently under investigation in our 
laboratory. Thus, although whether ES-62 acts via TLR4 
to modulate IL-22 expression by γδ T cells during CIA is 
still unclear, it is an attractive hypothesis in terms of 
allowing selective modulation of the immune response 
given that we have previously shown that 
ES-62-mediated down regulation of IL-17 production by 
T cells reflects inhibition of their activation by DCs 
[23] 
and that NK T cells, which do not express TLR4, are not 
affected by ES-62 in terms of either IL-17or 
IL-22production
[20]
 (Fig. 1).  
Phosphorylcholine (PC) mimics the ability of ES-62 
to increase IL-22 levels in the bloodstream of CIA 
animals. Collectively, our data indicate that ES-62 can 
selectively modify critical regulatoryIL-17/IL-22 
pathways in the CIA model. Of note, therapies based on 
its mode of action promoting resetting of the protective: 
pathogenic T cell effect or balance of this inflammatory 
axis that focus on the differential suppression of 
IL-17/IL-22-producing innate cell populations are 
perhaps less likely to leave the host open to opportunistic 
fungal infections, than current strategies involving novel 
biological agents like monoclonal IL-17 neutralizing 
antibodies. This new generation of immunomodulatorsis 
in phase II clinical trials (secukinomab 
[40]
, ixekizumab 
[41] 
and brodalumab 
[42]
), but already it seems clear that 
more studies are needed to establish their long-term 
safety as some reports showed increased rates of such 
infection concomitant with treatment 
[43-45]
. ES-62 thus 
presents certain advantages as a potential anti-arthritic 
treatment: reduced risk of immunosuppression since 
IL-17-driven responses are limited but not abrogated, 
regulation of a complex network of cells rather than a key 
regulatory molecule and the additional ability to trigger 
damage repair mechanisms, such as IL-22-mediated 
Figure 2. TLR4 expression by γδ T cells is associated with their production of IL-22in mice with Collagen-Induced Arthritis. 
Representative plots of the gating strategy for analysis of intracellular IL-17 and IL-22 expression by γδ TCR+ and CD49b+NK T cells in 
the DLN from a single CIA mouse following exvivo stimulation with PMA/ionomycinare shown (A). Expression of TLR4 was determined 
according to appropriate is otype controls (tinted grey histograms) in γδT cells and CD49b+NK T cells respectively. Data represent 
Mean Fluorescence Intensity (MFI) ± SD of DLN cells (B) from 5 individual mice(***p<0.001) undergoing CIA from a single experiment 
representative of two independent experiments 
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pathways of inflammation resolution and wound healing. 
However, as a large potentially immunogenic protein, 
ES-62 still presents important limitations preventing its 
translation into the clinic. Nevertheless, new ES-62-based 
interventional approaches can still be developed as the 
bioactive PC moiety, when conjugated to an "inert" 
carrier protein such as BSA, can also protect mice against 
CIA (Fig. 3A-B). Indeed, studies involving PC-BSA 
were the starting point for our development of small 
molecular analogues (SMAs) that mimic the 
anti-inflammatory ability of ES-62 in targeting 
pathogenic IL-17 responses in mouse models of arthritis 
and asthma
[9, 25]
 and provide prof of concept for 
helminth-based drugs in inflammatory disease. 
Although protection by PC-BSA against CIA also 
reflects down-regulation of pathogenic IL-17-dependent 
responses
[9]
, our earlier studies suggested that PC does 
not necessarily reproduce all of the potentially protective 
effects of ES-62. For example, whilst PC conjugated to 
ovalbumin (PC-OVA) also ameliorated joint pathology in 
CIA models, it did not reduce the levels of potentially 
pathogenic anti-collagen IgG2a antibodies that are 
additionally decreased in ES-62-treated mice 
[8]
. 
Therefore, we decided to investigate whether 
PC-BSA-mediated protection against CIA also reflected 
the up-regulation of IL-22 required for protection by 
Figure 3. PC-BSA protection against CIA is associated with upregulation of serum IL-22 
and IL-10. Mice undergoing CIA were treated with BSA (n=4) or PC-BSA (n=4). Arthritis scores 
(A)at day 32 after initial collagen injections are shown, expressed as mean scores ± SEM for 
BSA- or PC-BSA-treatment groups. Disease incidence is also shown (B), indicated by the % of 
mice developing a severity score ≥2. ** = p< 0.01. IL-22 (C&E) and IL-10 (D & F) levels were 
evaluated by ELISA in serum of naïve (n=3), BSA- (n=4) and PC-BSA-treated (n=4) individual 
mice and plotted as mean values of triplicate analyses (C & D). *p<0.05 and ***p<0.001.The 
correlations between IL-22 (E; n = 8, r = 0.6726, p = 0.0127) and IL-10(F; n = 8, r = 0.406, p = 
0.088) serum concentrations for all mice undergoing CIA (BSA- and PC-BSA-treated groups) 
and clinical scores are shown (E & F). 
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ES-62 
[23]
. Interestingly therefore, whilst as we have 
shown previously, CIA mice presented elevated levels of 
IL-22 in serum compared to naïve mice 
[23]
, it was found 
that such PC-BSA-treated mice exhibit significantly 
higher levels of IL-22 (3.5-fold increase, Fig.3C) and 
these serum levels of IL-22 inversely correlate with the 
clinical scores of the mice with CIA(Fig. 3E).Taken 
together, these findings corroborate our previous results 
observed with ES-62 and further support our hypothesis 
that the high levels of IL-22 observed in the serum of 
such mice during established disease, reflect the 
resolution of inflammation and joint damage properties of 
this cytokine in the CIA model
[23]
. 
Increased levels of IL-22 are also associated with 
elevated levels of IL-10 in serum obtained from 
PC-BSA-treated CIA mice. We have previously shown 
that protection against CIA in mice afforded by ES-62 is 
associated not only with inflammation-resolving IL-22 
responses, but also with elevated splenic IL-10 
production 
[7] 
which may reflect restoration of the levels 
of B cells with potential (IL-10-dependent) regulatory 
capacity 
[13]
. Interestingly, therefore, a recent study has 
Figure 4. Protective effects of ES-62 observed in the CIA model. ES-62 targets a complex cell 
network to regulate cytokine production and effector responses in the joint of CIA mice. In serum, 
ES-62/PC-BSA up-regulates IL-10 and IL-22, but strongly down-regulates IL-17 (1). In draining lymph 
nodes, IL-17 production by γδ T cells and conventional CD4 T cells, is downregulated by ES-62 via 
modulation of DC responses (2). This is reflected in vitro by ES-62 targeting DCs to down-regulate 
TLR-mediated production of IL-23, IL-6 and IL-1, resulting in reduced Th17 priming and inhibited induction 
of IL-17-producing γδ T cells. In addition, ES-62 directly inhibits IL-1-dependent differentiation of Th17 in 
vitro by downregulation of MyD88 (3). Analysis of joint cells by flow cytometry and immunohistochemistry 
(4) revealed that at the site of inflammation, ES-62 down-regulates the levels of antibody producing B 
cells and restores the levels of IL-10 producing B cells. In addition, the IL-17/IL-22 balance is reset with 
protective IL-22 responses desensitising synovial fibroblasts to IL-17, further suppressing 
IL-17-dependent inflammatory pathways, including the IL-6 production by synoviocytes and the 
subsequent recruitment of pro-inflammatory cells like neutrophils (5). Furthermore, the residual 
neutrophils infiltrating the joint exhibit a modulated phenotype and produce higher amounts of IL-22 (and 
lower levels of IL- -6), to perpetuate the protective mechanisms of ES-62 in the joint. 
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suggested that IL-22-mediated amelioration of CIA 
severity is associated with increased levels of IL-10
[46]
. 
Moreover, IL-22 has also recently been reported to 
suppress experimental autoimmune uveitis via generation 
of IL-10-producing regulatory CD11b
+
antigen presenting 
cells 
[47]
. Therefore, we decided to evaluate the levels of 
IL-10 in serum of PC-BSA-treated mice, to determine 
whether there was concomitant up-regulation of IL-22 
and IL-10 levels, as observed with ES-62.  Indeed, 
treatment with PC-BSA was found to restore the levels of 
serum IL-10 which had tended to be down-regulated in 
CIA mice to those observed in naive mice(Fig. 
3D):moreover, and consistent with a protective role for 
this cytokine, such IL-10 levels also inversely correlated 
with CIA articular disease scores (Fig.3F). These results 
suggest that PC-BSA is able to reproduce the ability of 
ES-62 to promote IL-10 production in the CIA model
[8]
: 
although the cell type responsible for such IL-10 
production is still unknown, it is possible that PC-BSA 
promotes IL-10-producing regulatory B cells, rather than 
regulatory T cells, as with ES-62 in CIA mice 
[13]
. 
Mechanistically, since neutralizing anti-IL-10 antibodies 
were shown to abrogate the protective effect of IL-22 in 
CIA 
[46]
, such restoration of IL-10 levels by PC-BSA 
might impact on DC-dependent priming of Th17 and 
IL-17-producing γδT cells, consistent with the reduced 
levels of IL-17 observed in serum of PC-BSA-treated 
CIA mice 
[9]
. Thus understanding the mechanisms 
responsible for controlling cytokine networks such as 
those resulting in the ES-62-mediated counter-regulation 
of IL-10/IL-22/IL-17 responses (Summarized in Fig. 4), 
rather than the analysis of the individual cytokines, may 
clarify the contradictory data relating to, for example, 
whether IL-22 is a pro- or anti-inflammatory mediator in 
RA.  
Concluding Remarks 
IL-22 was originally described as a pro-inflammatory 
mediator in RA. This reflects findings that mice deficient 
in this cytokine were resistant to developing CIA
[48]
as 
well as reports that IL-22 levels and Th22 cells are 
elevated in the serum of RA patients 
[21]
 and also that 
IL-22 has been shown to induce proliferation of human 
SF and promote RANKL production and 
osteoclastogenesis in vitro
[49]
. However, whilst IL-22 
levels are up-regulated in RA patients and IL-22 has been 
shown to be involved in bone damage and RANKL 
production, certain studies report that such IL-22 up 
regulation does not contribute to the induction of 
synovial inflammation 
[21, 49-51]
. Moreover, supporting our 
proposal of dual pathogenic and protective roles for 
IL-22 in RA based on the protective action ofES-62 in 
CIA 
[23]
, recent studies have also shown that IL-22 can 
play protective roles in CIA, via enhancing 
IL-10-mediated immunoregulation 
[46]
 and, as with 
ES-62, desensitizing SFs to IL-17 
[52]
. Collectively, these 
data suggest that the precise role of IL-22 in RA - 
protective versus pathogenic -probably depends on the 
inflammatory context. This is likely to especially be the 
case with respect to its differential effects on SFs, which 
in RA are subject to a complex pro-inflammatory cocktail 
involving cytokines, chemokines and alarmins generated 
by the hypoxic conditions pertaining in the arthritic joint. 
These results therefore question the hypothesis that serum 
IL-22 levels provide a pathogenic biomarker in 
established RA and may even suggest that IL-22 is 
upregulated in a homeostatic mechanism to limit and 
resolve joint inflammation and promote tissue repair. In 
any case, they dictate that therapies targeting IL-22 
should be reconsidered while the role of the cytokine in 
the initiation and progression of synovial inflammation in 
RA awaits full understanding.  
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